Evidence map›Paper›PMID 41824635›Full record

ReviewHepatology communications2026

The dual roles of natural killer cells in liver immunity and tolerance: Implications for health and disease.

Zhongheng Li, Yihang Gong, Linsen Ye, Wei Liu

Abstract readReview
In one paragraph

Review in Hepatology communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zhongheng LiGuangdong Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.ORCID 0009-0001-4195-3399
Yihang GongGuangdong Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Linsen YeGuangdong Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Wei LiuDepartment of Hepatic Surgery and Liver Transplantation Center, Organ Transplantation Institute, Organ Transplantation Research Center of Guangdong Province, Guangdong Province Engineering Laboratory for Transplantation Medicine, The Third Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen University, Guangzhou, China.ORCID 0000-0002-4935-7591

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The liver, a pivotal organ in immunity, functions as a central site with dual roles in immune defense and tolerance. Natural killer (NK) cells, a key subset of hepatic lymphocytes, display significant heterogeneity, with varied phenotypic and functional traits that enable them to perform essential roles in immune surveillance, maintain tissue homeostasis, and defend against pathogens and tumors. NK cell activation is tightly controlled by a balance between activating and inhibitory receptors, which orchestrates their cytotoxic, cytokine-producing, and immunoregulatory functions. They are vital participants in antiviral responses, tumor surveillance, fibrosis regulation, and liver regeneration. In chronic liver diseases such as viral hepatitis, fibrosis, and hepatocellular carcinoma (HCC), NK cell dysfunction, characterized by diminished cytotoxic function and altered receptor expression, contributes to disease progression. Emerging therapies, including chimeric antigen receptor-engineered NK (CAR-NK) cells and cytokine-based treatments, aim to restore NK cell functionality and harness their therapeutic potential for liver disease management. This review highlights the dual roles of NK cells in liver health and disease, emphasizing their significance in immune regulation, disease progression, and therapeutic innovation.

Indexed as

Immune ToleranceKiller Cells, NaturalLiverLiver DiseasesAnimalsHumanschronic liver diseasecytokineshepatocyteimmunotherapyphenotype

Identifiers

PMID41824635
PMCPMC12978837

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.